Verrucomicrobiae

Verrucomicrobiae is a taxonomic class of Gram-negative bacteria within the phylum Verrucomicrobiota, prominently represented in the human gastrointestinal tract by the species Akkermansia muciniphila (NCBI Taxonomy). This group plays a fundamental role in maintaining host health by specializing in the degradation of mucin, the primary carbohydrate component of the intestinal mucus layer (Derrien et al., 2004; PubMed: 15123531). This degradation process is not only a metabolic niche but also a signaling mechanism that promotes mucus turnover, strengthens the intestinal barrier, and produces beneficial metabolites like short-chain fatty acids (SCFAs). Clinically, the abundance of Verrucomicrobiae is frequently cited as a biomarker for metabolic health; higher levels are associated with leaner phenotypes and improved insulin sensitivity, while depletion is linked to obesity, type 2 diabetes, and inflammatory bowel diseases (de la Cuesta-Zuluaga et al., 2017; PubMed: 28863111). Furthermore, research has identified Verrucomicrobiae as a key determinant in the success of cancer treatments, with its presence significantly enhancing the efficacy of PD-1-based immune checkpoint inhibitors (Routy et al., 2018; PubMed: 29302014). Consequently, this bacterial class is a major focus for developing 'next-generation' probiotics and prebiotic interventions intended to modulate the microbiome for therapeutic benefit.

Other names

VerrucomicrobiaVerrucomicrobiotaVerrucomicrobia classAkkermansia-containing class

Verrucomicrobiae, specifically the member Akkermansia muciniphila, modulate host physiology by degrading intestinal mucin into short-chain fatty acids (SCFAs) like acetate and propionate, which activate G protein-coupled receptors (GPR41 and GPR43) to regulate glucose and lipid metabolism (Everard et al., 2013; PubMed: 23671105). They enhance intestinal barrier integrity by stimulating the expression of tight junction proteins such as occludin and zonula occludens-1 (ZO-1). Furthermore, specific outer membrane proteins, such as Amuc_1100, interact directly with Toll-like receptor 2 (TLR2) to modulate immune signaling and improve metabolic homeostasis (Plovier et al., 2017; PubMed: 27903520).